Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Alan J. Kivitz"'
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 675-689 (2024)
Abstract Introduction The aim of this work is to evaluate secukinumab vs. placebo in a challenging-to-treat and smaller US patient subpopulation of the international FUTURE 2–5 studies in patients with psoriatic arthritis (PsA). Methods Data were p
Externí odkaz:
https://doaj.org/article/82e8a3c103fb46598b98d83425a76465
Autor:
Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 1, Pp 53-70 (2022)
Abstract Introduction This exploratory analysis of FINCH 1 (NCT02889796) examined filgotinib (FIL) efficacy and safety in a subgroup of patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX; MTX-IR) who had four poor pr
Externí odkaz:
https://doaj.org/article/d5f278750ece4369b8287f893aae3cee
Autor:
Lubna Abuqayyas, Laurence E. Cheng, Marcia Teixeira dos Santos, Barbara A. Sullivan, Norma Ruiz‐Santiago, Hui Wang, Yanchen Zhou, Vishala Chindalore, Stanley Cohen, Alan J. Kivitz, Maximilian G. Posch, Jane R. Parnes
Publikováno v:
ACR Open Rheumatology, Vol 4, Iss 10, Pp 903-911 (2022)
Objective To assess the safety and biological activity of rozibafusp alfa, a first‐in‐class bispecific antibody–peptide conjugate targeting inducible costimulator ligand (ICOSL) and B cell activating factor (BAFF), in patients with rheumatoid a
Externí odkaz:
https://doaj.org/article/5676c94a2dbb4dc3a8d16a7cdd33da21
Autor:
Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 1, Pp 71-72 (2023)
Externí odkaz:
https://doaj.org/article/482e0de723eb4725b687f0331d72bd59
Autor:
Martin J. Bergman, Alan J. Kivitz, Dimitrios A. Pappas, Joel M. Kremer, Lixia Zhang, Anna Jeter, Johanna B. Withers
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 4, Pp 775-792 (2020)
Abstract Introduction The PrismRA® test identifies rheumatoid arthritis (RA) patients who are unlikely to respond to anti-tumor necrosis factor (anti-TNF) therapies. This study evaluated the clinical and financial outcomes of incorporating PrismRA i
Externí odkaz:
https://doaj.org/article/b28f75c23988432186a271042e8f815a
Autor:
Peter Nash, Laura C. Coates, Alan J. Kivitz, Philip J. Mease, Dafna D. Gladman, José A. Covarrubias-Cobos, Oliver FitzGerald, Dona Fleishaker, Cunshan Wang, Joseph Wu, Ming-Ann Hsu, Sujatha Menon, Lara Fallon, Ana Belén Romero, Keith S. Kanik
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 3, Pp 553-580 (2020)
Abstract Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the interim safety, tolerability, and efficacy of tofacitinib in PsA patients in OPAL Balance, a 3-year, open-label, long-te
Externí odkaz:
https://doaj.org/article/86b13f128d894de4aa055f152d42c856
Autor:
Karel Pavelka, Alan J. Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Yi Wang, Brian O. Porter, Anna Stefanska, Hanno B. Richards, Susanne Rohrer, the MEASURE 3 study group
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 2, Pp 119-127 (2020)
Objective Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis (AS), with response rates sustained for up to 5 years. Here, we report end‐of‐study 3‐year efficacy and safety results of secu
Externí odkaz:
https://doaj.org/article/a5c1efd6d4964e03b758b444acf10046
Autor:
Peter H. Schafer, Alan J. Kivitz, Jianglin Ma, Shimon Korish, Donna Sutherland, Li Li, Ada Azaryan, Jolanta Kosek, Mary Adams, Lori Capone, Eun Mi Hur, Douglas R. Hough, Garth E. Ringheim
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 1, Pp 101-119 (2019)
Abstract Introduction Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways. This study evaluated spebrutinib pharmacology and mec
Externí odkaz:
https://doaj.org/article/39d20490cb6e49508dbe1a45ca6893e9
Autor:
Mark C. Genovese, Maria W. Greenwald, Sergio R. Gutierrez-Ureña, Mario H. Cardiel, Jeffrey E. Poiley, Anna Zubrzycka-Sienkiewicz, Christine E. Codding, Annie Wang, Weizhong He, Rebecca Amos, Raul Vinueza, Xuegong Wang, Jay P. Garg, Alan J. Kivitz
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 4, Pp 503-520 (2019)
Abstract Introduction Peficitinib is a novel orally bioavailable, once-daily Janus kinase (JAK) inhibitor approved in Japan for the treatment of rheumatoid arthritis (RA). This 2-year extension study of two global phase IIb trials investigated the lo
Externí odkaz:
https://doaj.org/article/b2f958b58ad64477b1ce0db746636e51
Autor:
Alan J. Kivitz, Peter Nash, Hasan Tahir, Andrea Everding, Heřman Mann, Andrzej Kaszuba, Pascale Pellet, Albert Widmer, Luminita Pricop, Ken Abrams
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 3, Pp 393-407 (2019)
Abstract Introduction To assess the efficacy and safety of the subcutaneous (s.c.) secukinumab 150 mg with loading (150 mg) or without loading (150 mg no-load) regimen through 104 weeks in patients with active psoriatic arthritis (PsA) in the FUTURE
Externí odkaz:
https://doaj.org/article/4baf3af6552740698eb358c503164425